Segment Reporting (Tables)

3 Months Ended

Mar. 31, 2024

Segment Reporting [Abstract]

Reconciliation of Operating Profit (Loss) from Segments to Consolidated

A reconciliation of the totals reported for the reportable segments to the applicable line items within our accompanying unaudited consolidated statements of operations is as follows (in millions, except percentages). Prior period amounts have been restated at constant currency to conform to current year presentation.

	Three Months Ended March 31,
Net Sales	2024		2023
MedSurg	$	1,402	$	1,266
Cardiovascular	2,426		2,072
Total net sales of reportable segments	3,827		3,337
Impact of foreign currency fluctuations	29		52
	$	3,856	$	3,389

Income (loss) before income taxes
MedSurg	$	474	$	409
Cardiovascular	653		553
Total operating income of reportable segments	1,128		963
Unallocated amounts:
Corporate expenses, including hedging activities and impact of foreign currency fluctuations on operating income of reportable segments	(115)		(98)
Goodwill and other intangible asset impairment charges, acquisition/divestiture-related net charges (credits), restructuring and restructuring-related net charges (credits), certain litigation-related net charges (credits) and EU MDR implementation costs	(124)		(110)
Amortization expense	(214)		(203)
Operating income (loss)	675		552
Other income (expense), net	(67)		(108)
Income (loss) before income taxes	$	608	$	444

	Three Months Ended March 31,
Operating income margin of reportable segments	2024		2023
MedSurg	33.8	%	32.3	%
Cardiovascular	26.9	%	26.7	%